


Thalidomide-O-C5-acid

Cat. No.:	HY-131889
CAS No.:	2087490-48-8
Molecular Formula:	C ₁₉ H ₂₀ N ₂ O ₇
Molecular Weight:	388.37
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (643.72 mM; Need ultrasonic)																	
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent Concentration</th> <th rowspan="2">Mass</th> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>1 mM</td> <td>2.5749 mL</td> <td>12.8743 mL</td> <td>25.7486 mL</td> </tr> <tr> <td>5 mM</td> <td>0.5150 mL</td> <td>2.5749 mL</td> <td>5.1497 mL</td> </tr> <tr> <td>10 mM</td> <td>0.2575 mL</td> <td>1.2874 mL</td> <td>2.5749 mL</td> </tr> </tbody> </table>	Solvent Concentration	Mass	1 mg	5 mg	10 mg	1 mM	2.5749 mL	12.8743 mL	25.7486 mL	5 mM	0.5150 mL	2.5749 mL	5.1497 mL	10 mM	0.2575 mL	1.2874 mL	2.5749 mL
Solvent Concentration	Mass			1 mg	5 mg	10 mg												
		1 mM	2.5749 mL	12.8743 mL	25.7486 mL													
5 mM	0.5150 mL	2.5749 mL	5.1497 mL															
10 mM	0.2575 mL	1.2874 mL	2.5749 mL															
	Please refer to the solubility information to select the appropriate solvent.																	
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.36 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.36 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.36 mM); Clear solution 																	

BIOLOGICAL ACTIVITY

Description	Thalidomide-O-C5-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology ^[1] .
IC₅₀ & Target	Cereblon
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. *Front Cell Dev Biol.* 2021;9:629326. Published 2021 Mar 11.

[2]. Nalawansa DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. *Cell Chem Biol.* 2020;27(8):998-1008.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA